Precigen earnings release, August 4, 2026

Precigen, Inc. (PGEN) · Form 8-K, Item 2.02 · Filed · SEC filing

Precigen Reports Second Quarter 2026 Financial

Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

GERMANTOWN, MD, August 4, 2026 – Precigen, Inc.

(Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced second quarter 2026 financial results and business updates.

“We delivered a historic second quarter, with the rapid adoption of PAPZIMEOS demonstrating the strength of our groundbreaking science and innovative commercial strategy,” said Helen Sabzevari, PhD, President and CEO of Precigen. “This momentum provides a strong foundation for our next phase of growth as we work to expand PAPZIMEOS globally and into the pediatric population. PAPZIMEOS demonstrates the AdenoVerse platform’s ability to target HPV-associated diseases. We are building on that validated capability by advancing PRGN-2009 in HPV-driven cancers, with a pipeline update expected by year-end. With growing commercial momentum, a validated platform, and multiple opportunities ahead, we believe Precigen is well positioned to deliver sustained value for patients across various indications, the broader healthcare community, and our shareholders.”

“We continue to see the key elements of the

PAPZIMEOS commercial launch drive revenue growth: 100% field engagement with our initial target accounts, active patient and HCP campaigns, a permanent J-code supporting access and site activations, payer coverage across nearly all insured US lives, growing physician consensus reflected in a RRP position paper, and continued patient hub enrollments,” said Phil Tennant, Chief Commercial Officer of Precigen.

“This progress translated into strong quarterly revenue growth and increasing adoption across major medical centers and community practices as PAPZIMEOS becomes established as a new standard of care for adults with RRP. We remain focused on converting demand into treated patients and further expanding access to PAPZIMEOS across the RRP community.”

KEY PROGRAM HIGHLIGHTS

PAPZIMEOS®

: First-line

Standard of Care for the Treatment of Adults with RRP

PAPZIMEOS (zopapogene imadenovec-drba) is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against HPV 6 and HPV 11 proteins in patients with recurrent respiratory papillomatosis (RRP). PAPZIMEOS has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with RRP.

Authorization Application (MAA) submitted in November 2025 for zopapogene imadenovec for the treatment of adults with RRP. PAPZIMEOS has been granted orphan drug designation from the European Commission.

PRGN-2009 AdenoVerse®

Immunotherapy in HPV-associated

Cancers

PRGN-2009 is an investigational AdenoVerse immunotherapy designed to activate the immune system to recognize and target HPV-associated cancers.

FINANCIAL RESULTS

“We are thrilled to report that Precigen achieved profitability in the second quarter, marking a significant milestone for the company. Net income was driven by strong PAPZIMEOS revenue of $53.1 million. As we progress through the third quarter of 2026, we are seeing continued growth in PAPZIMEOS demand," said Harry Thomasian Jr., Chief Financial Officer of Precigen. “Based upon our current revenue trajectory and present financial forecast, we continue to believe that our current cash position and anticipated cash to be received from PAPZIMEOS sales will fund operations through cash flow break-even by the end of 2026.”

Second Quarter 2026 Financial Results Compared to Prior Year Period

Total revenues were $55.0 million for the three months ended June 30, 2026, an increase of $54.1 million compared to the three months ended June 30, 2025. The significant increase in total revenues was primarily due to the recording of commercial sales of PAPZIMEOS. Revenues related to the sale of PAPZIMEOS for the three months ended June 30, 2026 were $53.1 million.

Cost of products and services increased by $1.7 million, compared to the three months ended June 30, 2025, almost entirely due to costs related to the recording of commercial sales of

PAPZIMEOS following its FDA approval in August 2025. Prior to regulatory approval, costs associated with the production of PAPZIMEOS were expensed as research and development in accordance with the Company’s accounting policy. Upon FDA approval and the commencement of commercial sales, these costs are now capitalized as inventory and recognized in cost of product and services as product is sold.

R&D expenses decreased by $4.2 million, compared to the three months ended June 30, 2025, primarily due to the change in the accounting treatment of PAPZIMEOS manufacturing costs. The

Company expects that R&D expenses will increase as the year progresses.

SG&A expenses increased by $6.1 million, compared to the three months ended June 30, 2025. This increase was primarily driven by commercial activities related to PAPZIMEOS following its

FDA approval in August 2025. The higher expenses reflect increased costs to support commercialization, expanded marketing and promotional activities to drive product awareness and adoption, and increased personnel costs, including stock compensation expense.

In the three months ended June 30, 2025, the Company recorded $3.9 million in impairment related to its Exemplar reporting unit with no comparable charge in the second quarter of 2026.

Total other expense, net was $2.6 million for the three months ended June 30, 2026 compared to other income, net of $5.1 million for the three months ended June 30, 2025, a change of $7.7 million. This change was primarily attributable to the absence of a $4.5 million gain related to the decrease in the fair value of warrant... (truncated)ily relates to an increase of $3.0 million in interest expense related to long term debt that originated in the third quarter of 2025.

Net income was $20.1 million, or $0.06 per basic and $0.05 per diluted share for the three months ended June 30, 2026, compared to a net loss of $26.6 million, or $(0.09) per basic and diluted share, for the three months ended June 30, 2025.

First Six Months 2026 Financial Results Compared to Prior Year Period

Total revenues were $78.2 million for the six months ended June 30, 2026, an increase of $76.0 million compared to the six months ended June 30, 2025. The significant increase in total revenues was primarily due to the recording of commercial sales of PAPZIMEOS. Revenues related to the sale of PAPZIMEOS for the six months ended

June 30, 2026 were $74.7 million.

Cost of products and services increased by $3.2 million, compared to the six months ended June 30, 2025, almost entirely due to costs related to the recording of commercial sales of

PAPZIMEOS following its FDA approval in August 2025. Prior to regulatory approval, costs associated with the production of PAPZIMEOS were expensed as research and development in accordance with the Company’s accounting policy. Upon FDA approval and the commencement of commercial sales, these costs are now capitalized as inventory and recognized in cost of product and services as product is sold.

R&D expenses decreased by $9.0 million, compared to the six months ended June 30, 2025, primarily due to the change in the accounting treatment of PAPZIMEOS manufacturing costs. The Company expects that R&D expenses will increase as the year progresses.

SG&A expenses increased by $14.8 million, compared to the six months ended June 30, 2025. This increase was primarily driven by commercial activities related to PAPZIMEOS following its

FDA approval in August 2025. The higher expenses reflect increased costs to support commercialization, expanded marketing and promotional activities to drive product awareness and adoption, and increased personnel costs, including stock compensation expense.

In the six months ended June 30, 2025, the Company recorded $3.9 million in impairment related to its Exemplar reporting unit with no comparable charge in the six months ended June 30,

2026.

Total other expense, net decreased by $21.9 million, compared to the six months ended June 30, 2025. This decrease was primarily attributable to the absence of a $28.0 million charge related to the increase in the fair value of warrant liabilities that was recorded in the prior-year period. The remaining change (an increase in other expense) primarily relates to an increase of $5.9 million in interest expense related to long-term debt that was entered into in the third quarter of 2025.

Net income was $12.1 million, or $0.03 per basic and diluted share for the six months ended June 30, 2026, compared to a net loss of $80.8 million, or $(0.27) per basic and diluted share, for the six months ended June 30, 2025.

###

Precigen: Advancing

Medicine with Precision®

Precigen (Nasdaq:

PGEN) is a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization.

With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on

LinkedIn or

YouTube.

Trademarks

Precigen, PAPZIMEOS,

AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited) (Amounts in thousands, except share Three Months Ended June 30, Six Months Ended June 30, and per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
RevenuesProduct revenues, net53,2624175,090244
RevenuesService revenues1,7168153,1401,953
RevenuesTotal revenues54,97885678,2302,197
Operating ExpensesCost of products and services2,8051,0925,3642,192
Operating ExpensesResearch and development7,28211,48812,92021,966
Operating ExpensesSelling, general and administrative22,24916,13343,29828,492
Operating ExpensesImpairment of goodwill3,9073,907
Operating ExpensesTotal operating expenses32,33632,62061,58256,557
Operating ExpensesOperating income (loss)22,642-31,76416,648-54,360
Other Income (Expense), NetChange in fair value of warrant liabilities4,460-28,021
Other Income (Expense), NetInterest expense-2,953-5,861-1
Other Income (Expense), NetInterest income3666961,0491,614
Other Income (Expense), NetOther income (expense), net16-31306-24
Other Income (Expense), NetTotal other income (expense), net-2,5715,125-4,506-26,432
Other Income (Expense), NetIncome (loss) before income taxes20,071-26,63912,142-80,792
Other Income (Expense), NetIncome tax expense-3-3
Other Income (Expense), NetNet income (loss)20,071-26,64212,142-80,795
Net income (loss) per shareNet income (loss) per share, basic0.06-0.090.03-0.27
Net income (loss) per shareNet income (loss) per share, diluted0.05-0.090.03-0.27
Net income (loss) per shareWeighted average shares outstanding, basic356,893,568296,434,726355,599,477295,164,303
Net income (loss) per shareWeighted average shares outstanding, diluted413,686,865296,434,726412,552,647295,164,303

Balance Sheet

June 30, 2026 — (Unaudited) (in thousands)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents16,32930,234
Current assetsShort-term investments21,87967,624
ReceivablesTrade, net71,8663,916
ReceivablesOther178446
ReceivablesInventory20,2459,581
ReceivablesPrepaid expenses and other3,8873,434
ReceivablesTotal current assets134,384115,235
ReceivablesLong-term investments4902,511
ReceivablesProperty, plant and equipment, net12,80213,758
ReceivablesIntangible assets, net2,5453,182
ReceivablesGoodwill15,23215,232
ReceivablesRight-of-use assets4,1354,679
ReceivablesOther assets708908
ReceivablesTotal assets170,296155,505
Current liabilitiesAccounts payable5,30411,985
Current liabilitiesAccrued compensation and benefits6,49810,199
Current liabilitiesOther accrued liabilities16,21210,993
Current liabilitiesIndemnification accruals2,476
Current liabilitiesDeferred revenue284517
Current liabilitiesCurrent portion of lease liabilities1,0551,136
Current liabilitiesTotal current liabilities29,35337,306
Current liabilitiesLong-term debt93,88093,174
Current liabilitiesLease liabilities, net of current portion3,4103,980
Current liabilitiesOther long-term liabilities77134
Current liabilitiesTotal liabilities126,720134,594
Shareholders' equityAdditional paid-in capital2,372,8112,362,252
Shareholders' equityAccumulated deficit-2,329,206-2,341,348
Shareholders' equityAccumulated other comprehensive (loss) income-297
Shareholders' equityTotal shareholders' equity43,57620,911
Shareholders' equityTotal liabilities and shareholders' equity170,296155,505
Full release

Statement Regarding Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities

Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,”

“plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,”

“strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company’s business and business plans, the success of efforts to commercialize PAPZIMEOS®

(zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults including the revenue that the Company expects to realize from such efforts, the Company’s ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS, the ability of PAPZIMEOS to treat RRP, the Company’s future financial and operational results including the Company’s ability to reach quarterly profitability and cash flow break-even, and the Company’s ability to commence clinical studies or complete ongoing clinical studies for the Company’s clinical and pre-clinical stage candidates. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the... (truncated) Commission.

Investor Contact:

Steven M. Harasym

Tel: +1 (202) 365-2563 investors@precigen.com

Media Contact:

Donelle M. Gregory press@precigen.com

Precigen, Inc. and Subsidiaries

Consolidated Balance Sheets

(Unaudited)

Precigen, Inc. and Subsidiaries

Consolidated Statement of Operations

(Unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Precigen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.